In a transgenic mouse model, overexpressing human α–syn under the mThy1 promotor (Parkinson mouse model), researchers have proved that the new SV2A-radioligand developed at CRC is a valid biomarker to study the loss of synaptic terminals appearing before the occurrence of behavioral disturbances.

Contact [] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.